Guobang Pharma Ltd.

Shanghai Stock Exchange 605507.SS

Guobang Pharma Ltd. Total Non-Current Liabilities for the year ending December 31, 2023: USD 66.88 M

Guobang Pharma Ltd. Total Non-Current Liabilities is USD 66.88 M for the year ending December 31, 2023, a 1,661.69% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Guobang Pharma Ltd. Total Non-Current Liabilities for the year ending December 31, 2022 was USD 3.80 M, a 73.93% change year over year.
Guobang Pharma Ltd. Total Non-Current Liabilities for the year ending December 31, 2021 was USD 2.18 M, a -94.56% change year over year.
Guobang Pharma Ltd. Total Non-Current Liabilities for the year ending December 31, 2020 was USD 40.13 M, a -50.94% change year over year.
Guobang Pharma Ltd. Total Non-Current Liabilities for the year ending December 31, 2019 was USD 81.81 M, a 859.39% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

Shanghai Stock Exchange: 605507.SS

Guobang Pharma Ltd.

CEO	Mr. Yuda Gong
IPO Date	Aug. 2, 2021
Location	China
Headquarters	No. 60, Xingmei Avenue
Employees	4,231
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Cosmetics Personal Care Pet Food Plastics Vaccines

Description

Guobang Pharma Ltd. engages in the research and development, production, and sale of medical products for human and animals in China. It offers medical products, including APIs, medication intermediates related to the API, and formulations; and veterinary products, such as APIs for animals, additives, and formulations. The company was founded in 1996 and is based in Xinchang, China.

Key trends

Past 5 years